CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer (NCT03546361)

🧪 Interventions in This Study

• Autologous Dendritic Cell-Adenovirus CCL21 Vaccine (BIOLOGICAL)
• Pembrolizumab (BIOLOGICAL)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Participants with histologically confirmed diagnosis of NSCLC will be enrolled in this study.
2. Stage IV pathologically proven NSCLC.
3. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
4. Must have received prior systemic anti-cancer therapy for advanced disease that includes either:
5. A PD-1 and/or PD-L1 inhibitor in patients without a sensitizing EGFR mutation and/or ALK gene rearrangement or.
6. Have received prior tyrosine kinase inhibitor therapy in patients with a sensitizing EGFR mutation and/or ALK gene rearrangement. For patients with sensitizing EGFR mutations, prior therapy must include osimertinib if a T790M mutation in the EGFR gene has been documented, and for patients with ALK gene rearrangements, prior therapy must include a second generation ALK inhibitor (e.g. alectinib, brigatinib, ceritinib). Note: For this group, prior cytotoxic chemotherapy is permitted, but prior therapy with a PD-1 or PD-L1 inhibitor is not permitted.
7. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1.
9. Absolute neutrophil count (ANC) \>= 1500/uL.
10. Platelets \>= 100,000/uL.
11. Hemoglobin \>= 9.0 g/dL or \>= 5.6 mmol/L.
12. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lung Non-Small Cell Carcinoma

• Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer — Buffalo, New York
• Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD — Los Angeles, California
• Gilteritinib for the Treatment of ALK NSCLC — Los Angeles, California
• Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer — Buffalo, New York
• A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment — Jonesboro, Arkansas

Explore by condition: All Lung Non-Small Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.